e events and financial performance. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our anticipated results. We discuss in detail the factors that may affect the achievement of our forward-looking statements in our Annual Report on Form 10-K filed with the SEC. In particular, we cannot be certain that we will ever achieve sustained profitability, that the rate of reimbursement for PTNS treatments will be adequate to justify the cost of our product, that other Medicare carriers or private payers will provide coverage for this treatment or that existing carriers and payers will not change their coverage decisions, or that any of the other risks identified in our 10-K will not adversely affect our expectations as described in these forward-looking statements.For Further Information: Uroplasty, Inc.
David Kaysen, President and CEO, or
Medi Jiwani, Vice President, CFO, and
Treasurer
952.426.6140 EVC Group
Doug Sherk/Jenifer Kirtland (Investors)
415.896.6820
Chris Gale (Media)
646.201.5431 UROPLASTY, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(Unaudited)Three Months EndedNine Months EndedDecember 31,December 31,2010200920102009Net sales
$3,492,067$3,068,142$9,772,389$8,880,546Cost of goods sold
604,566505,3991,709,7311,592,443Gross profit
2,887,5012,562,7438,062,6587,288,103Operating expensesGeneral and administrative
861,183639,6082,608,8682,201,199Research and development
423,794401,4811,296,4311,365,194Selling and marketing
2,871,4561,702,9006,877,4025,728,242Amortization
211,058211,189632,508634,5054,367,4912,955,17811,415,2099,929,140Operating loss
(1,479,990)(392,435)(3,352,551)(2,641,037)Other income (expense)Interest income
21,13521,46852,76277,097Interest expense
(652)(1,291)(4,537)(10,986)Foreign currency exchange gain
'/>"/>
SOURCE Uroplasty, Inc. Copyright©2010 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 Related medicine technology :1.
Uroplasty to Issue Third Quarter 2011 Results on January 27, 20112.
Uroplasty Announces Addition of Robert Kill to its Board of Directors3.
Additional Regional Medicare Carrier Initiates Coverage for Posterior Tibial Nerve Stimulation (PTNS) Delivered via Uroplastys Urgent® PC Neuromodulation System4.
Uroplasty Inc. Announces CPT® Category I Code and Associated Reimbursement Value for Posterior Tibial Nerve Stimulation5.
Uroplasty Reports Financial Results for the Second Quarter FY20116.
Uroplasty to Issue Second Quarter 2011 Results on October 27, 20107.
Uroplasty to Present at The 5th Annual JMP Securities Healthcare Conference8.
Coverage Initiated by Two Regional Medicare Carriers for Posterior Tibial Nerve Stimulation (PTNS) Delivered Via Uroplastys Urgent® PC Neuromodulation System9.
Uroplasty to Present at Global Hunter Securities Inaugural Healthcare Conference10.
Uroplasty Reports Results for Second Quarter FY201011.
Uroplasty to Issue Second Fiscal Quarter Results on November 2, 2009